Target intelligence / Profile preview

NF-κB signaling pathway in macrophages (NF-κB pathway)

Target
NF-κB pathway
Molecular classification
Signaling pathway, Transcription factor (component, e.g., NF-κB proteins), Receptor (initiation via pattern recognition receptors, cytokine receptors), Enzyme (intermediate kinases such as IKK)
01

Overview

The NF-κB signaling pathway in macrophages is a major intracellular signaling cascade that integrates upstream inflammatory cues—typically via pattern recognition receptors, cytokine receptors (notably the TNF receptor superfamily), and other immune sensors—to activate the NF-κB family of transcription factors. Upon activation (usually by infection, tissue damage, or cytokines like TNF-α), the pathway leads to the degradation of IκB inhibitory proteins, nuclear translocation of NF-κB, and transcription of a battery of genes that control inflammation, immune activation, cell survival, and apoptosis. Key cytokine outputs include pro-inflammatory TNF-α and the anti-inflammatory cytokine IL-10; the balance between these (and their complex cross-regulation) shapes the outcome of immune responses and is implicated in numerous diseases, especially chronic inflammation, infection, and cancer. This pathway is a major focus for therapeutic modulation, but targeting must be precise to avoid immunosuppression or paradoxical inflammation.

Other names
NF-κB pathwayCanonical NF-κB signalingMacrophage NF-κB signaling cascade
02

Mechanism of action

Inhibition of TNF-alpha to suppress inflammatory output; Inhibition of IKK or NF-κB to reduce transcription of pro-inflammatory genes; Blocking surface receptors (e.g., anti-TNF biologics prevent TNF-α from binding to receptor); Augmentation of IL-10 or STAT3 pathway to enhance anti-inflammatory signaling

03

Biological functions

Immune responseSignal transductionCytokine productionInflammatory responseCell survivalCell proliferationCell death
04

Disease associations

InflammationCancerAutoimmune diseaseInfectionCardiovascular diseaseNeurodegenerative disease
05

Safety considerations

Immunosuppression (increased risk of infection with pathway inhibition)Cytokine imbalance leading to autoimmune phenomena or systemic inflammationPoor efficacy of IL-10 based therapies due to pathway cross-talk and antagonism (e.g., TNF-α blocks IL-10 signals)
06

Interacting drugs

Anti-TNF agents (e.g., infliximab, adalimumab – target TNF-α)

4 more in the full profile.

07

Biomarkers

TNF-alpha (for pathway activation and drug efficacy)IL-10 (monitoring anti-inflammatory activity)Phosphorylation status of NF-κB, IκB, or STAT3SOCS3 expression (downstream of IL-10/STAT3 activation)

Beyond the preview

Go deeper on NF-κB signaling pathway in macrophages (NF-κB pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NF-κB signaling pathway in macrophages (NF-κB pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call